Abstract: Disclosed are hydroxamic and carboxylic acid derivatives which are useful inhibitors of matrix metalloproteinase and/or TNF.alpha.-mediated diseases, including degenerative diseases and certain cancers.

Abstract: Compounds of formula (I) having MMP and TNF inhibitory activity.

Abstract: For the treatment of cancer, inflammation, and other conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or enzymes involved in the shedding of L-selectin, CD23, the TNF receptors, IL-1 receptors, or IL-6 receptors, disclosed are compounds of the general formulaB--X--(CH.sub.2).sub.m --(CR.sup.1 R.sup.2).sub.n --W--COY.

Abstract: The subject invention concerns mercaptoalkylacyl compounds of formula (I): ##STR1## The compounds of the subject invention can be used to inhibit matrix metalloproteinases and/or TNF.alpha.- and L-selectin sheddase-mediated diseases including degenerative diseases and cancers. The subject invention also concerns methods of using the compounds of the invention to treat or prevent conditions associated with matrix metalloproteinases or that are mediated by TNF.alpha. or L-selectin sheddase.

Abstract: Compounds of the formula ##STR1## have therapeutic utility, as inhibitors of phosphodiesterase IV and TNF release.

Abstract: A compound of formula (i) ##STR1## has therapeutic utility via inhibition of phosphodiesterase and THF release.

Abstract: Compounds of formula (I) ##STR1## are useful as therapeutic agents, by virtue of having MMP and TNF inhibitory activity.

Abstract: Peptidyl compounds having an imidazole substituent have therapeutic utility via their inhibitory effect on metalloproteinases and tumour necrosis factor.

Abstract: Dipeptide compounds have therapeutic utility, inter alia, as metalloproteinase and TNF inhibitors.

Abstract: Compounds having the formula (i), ##STR1## wherein the groups R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined herein. The compounds of the present invention can be utilized to treat disease states capable of being modulated by inhibition of proteins which mediate cellular activity, such as tumor necrosis factor (TNF) and/or phosphodiesterase IV (PDE IV).

Abstract: Peptidyl compounds have therapeutic utility via MMP and TNF inhibitory activity.

Abstract: Compounds having the formula (i), ##STR1## wherein the groups R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined herein. The compounds of the present invention can be utilized to treat disease states capable of being modulated by inhibition of proteins which mediate cellular activity, such as tumor necrosis factor (TNF) and/or phosphodiesterase IV (PDE IV).

Abstract: Compounds of the formula (i) ##STR1## have therapeutic utility via inhibition of TNF or phophodiesterase.

Abstract: The subject invention concerns compounds of formula (I): whereinn=1 or 2;R.sup.1 is H, NH.sub.2 or halogen;R.sup.2 is H or NH.sub.2 ;R.sup.3 represents the group CR.sup.6 R.sup.7 R.sup.8 where R.sup.6, R.sup.7 and R.sup.8 are the same or different and are each H, C.sub.1-6 alkyl or C.sub.1-6 haloalkyl;R.sup.4 and R.sup.5 are the same or different and are selected from the group consisting of H, CO.sub.2 H, CO.sub.2 C.sub.1-6, NHSO.sub.2 CF.sub.3, tetrazole and (CR.sup.9 R.sup.10).sub.p (Y).sub.q (CR.sup.9 R.sup.10).sub.t Z where (CR.sup.9 R.sup.10), or (CR.sup.9 R.sup.10).sub.t is straight or branched chain bearing the substituents R.sup.9 and R.sup.10 when p or t>1;R.sup.9 and R.sup.10 are the same or different and are each C.sub.0-6 alkyl-Z;p=1-3;q=0 or 1;t=0-4, provided that t>0 when q=1;Y=O, NH or S(O).sub.m where m=0-2; andZ is selected from a group consisting of H, CN, CO.sub.2 H, CO.sub.2 C.sub.1-6 alkyl, NHSO.sub.2 CF.sub.3 tetrazole, triazole, CONH.sub.2, CON(C.sub.1-6 alkyl).sub.2, CONH(C.sub.

Abstract: 1-Alkyl-substituted-quinolone-3-carboxamides have therapeutic utility via inhibition of Phosphodiesterase IV esterase and/or Tumour Necrosis Factor activity. The compounds of the invention have the general formula (I): ##STR1## The compounds of the invention encompassed by formula (I) include enantiomers, diastereoisomers and mixtures, including racemic mixtures.

Abstract: Described herein are compounds of formula (I): ##STR1## which have MMP and TNF inhibitory activity.

Abstract: Compounds of formula (I) ##STR1## wherein n=1 or 2;R.sup.1 is H, NH.sub.2 or halogen;R.sup.2 is H or NH.sub.2 ;R.sup.3 represents the group ##STR2## where m=0 or 1; R.sup.4 and R.sup.5 are the same or different and are each H, CO.sub.2 H, CO.sub.2 C.sub.1-6 alkyl, NHSO.sub.2 CF.sub.3, tetrazole, (CR.sup.6 R.sup.7).sub.p (Y).sub.q (CR.sup.6 R.sup.7).sub.t Z where (CR.sup.6 R.sup.7)p or (CR.sup.6 R.sup.7).sub.t may be straight or branched chain bearing the substituents R.sup.6 and R.sup.7 when p and t>1; R.sup.6 and R.sup.7 are the same or different and are each C.sub.0-6 alkyl-Z;p=1-3;q=0 or 1;t=0-4, provided that t>0 wgeb q=1;Y is NH, O, S(O)u where u=0-2;Z is H, CN, CO.sub.2 H, CO.sub.2 C.sub.1-6 alkyl, NHSO.sub.2 CF.sub.3, tetrazole, triazole, CONH.sub.2, CON(C.sub.1-6 alkyl).sub.2, CONH(C.sub.1-6 alkyl), SO.sub.2 NH (C.sub.1-6 alkyl) or SO.sub.2 N(C.sub.1-6 alkyl).sub.2 ; or a salt, soluate or hydrate thereof.

Abstract: The subject invention pertains to quinolinesulfonamides. The subject compounds can be used to treat disease states, such as those that are associated with proteins that mediate cellular activity, for example, by inhibiting phosphodiesterase IV (PDE IV) or tumor necrosis factor (TNF). The invention also pertains to methods of treating disease states, including those states capable of being modulated by inhibition of PDE IV or TNF.

Abstract: 1,3-Disubstituted-zanthines have therapeutic utility via TNF or phosphodiesterase inhibition.

Abstract: The subject invention concerns novel compounds of the general formula (i) ##STR1## that are useful in treating disease states, such as those states associated with proteins that mediate cellular activity. The compounds of the subject invention can be used, for example, to inhibit tumor necrosis factor and/or phosphodiesterase IV, The subject invention also concerns methods for treating disease states using the compounds of the invention.